XtalPi Holdings Limited (HKEX: 2228) is a quantum physics‑based, AI‑powered R&D platform company that focuses on drug discovery and materials science, leveraging AI, quantum physics and robotics to accelerate innovation. Founded in 2015 and headquartered in Shenzhen with operations in China and the United States, XtalPi partners with global pharmaceutical, biotech and materials companies to improve the speed, scale, novelty and success rate of R&D.

Main products and businesses

• AI drug discovery solutions
  XtalPi provides end‑to‑end drug discovery solutions spanning hit identification, lead optimization and pre‑clinical candidate design, powered by its hybrid AI + quantum mechanics engine and high‑performance cloud computing. Its platforms, such as XMolGen for small‑molecule design and related AI prediction tools, can screen and design billions of molecules in silico before validation in automated robotic labs.

• Robotics and automation platforms
  The company operates highly automated wet labs that integrate robotics, digitalization and AI‑driven workflows for solid‑state R&D, automated chemical synthesis and high‑throughput experimentation, creating a closed feedback loop between “dry lab” computation and “wet lab” experiments.

• Materials‑science and cross‑industry R&D services
  Beyond pharmaceuticals, XtalPi offers materials‑science R&D services for sectors such as energy, agriculture, advanced chemicals and cosmetics, applying its computation‑plus‑automation platform to optimize material properties (for example, in batteries and solar materials).

Key advantages

• Integrated “AI + quantum physics + robotics” platform
  XtalPi’s core advantage lies in its tightly integrated platform combining first‑principles quantum calculations, AI models, cloud supercomputing and robotic automation, enabling iterative improvement between computational predictions and experimental data.

• Strong global partnerships and investor base
  The company has collaborated with leading pharma companies such as Pfizer and Eli Lilly and has attracted blue‑chip investors including SoftBank Vision Fund, Tencent, Google and others, validating its technology and business model.

• Scalable, data‑rich R&D engine
  With petabyte‑scale datasets of molecular and materials properties and continuously expanding model libraries, XtalPi can systematically explore vast chemical and material spaces, helping customers reduce experimental cycles and R&D costs.